Metsera (NASDAQ:MTSR) Shares Gap Up – What’s Next?

Metsera Inc. (NASDAQ:MTSR) shares gapped up prior to trading on Tuesday . The stock had previously closed at $60.73, but opened at $68.90. Metsera shares last traded at $70.46, with a volume of 2,920,830 shares traded.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on MTSR shares. Leerink Partnrs cut Metsera from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, September 24th. Wall Street Zen raised Metsera from a “sell” rating to a “hold” rating in a research note on Wednesday, October 1st. Weiss Ratings reissued a “sell (d)” rating on shares of Metsera in a research note on Wednesday, October 8th. Bank of America increased their price target on Metsera from $45.00 to $50.00 and gave the company a “buy” rating in a research note on Thursday, August 28th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Metsera in a research note on Wednesday, September 3rd. Four investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $55.75.

Metsera Price Performance

The firm has a fifty day simple moving average of $46.57 and a 200-day simple moving average of $35.93. The firm has a market cap of $7.68 billion and a P/E ratio of -14.00.

Institutional Trading of Metsera

Several institutional investors and hedge funds have recently modified their holdings of the stock. Osaic Holdings Inc. increased its position in shares of Metsera by 45.5% during the second quarter. Osaic Holdings Inc. now owns 946 shares of the company’s stock valued at $27,000 after acquiring an additional 296 shares during the last quarter. BNP Paribas Financial Markets increased its position in Metsera by 100.0% in the second quarter. BNP Paribas Financial Markets now owns 1,600 shares of the company’s stock worth $46,000 after buying an additional 800 shares during the last quarter. Strs Ohio purchased a new stake in Metsera in the first quarter worth $76,000. Virtus Investment Advisers LLC purchased a new stake in Metsera in the second quarter worth $77,000. Finally, Amalgamated Bank increased its position in Metsera by 225.2% in the third quarter. Amalgamated Bank now owns 1,730 shares of the company’s stock worth $91,000 after buying an additional 1,198 shares during the last quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.